What is the story about?
What's Happening?
Cambrex, through its subsidiary Snapdragon Chemistry, has expanded its active pharmaceutical ingredient (API) facility in Waltham, Massachusetts, enhancing its peptide manufacturing capabilities. The expansion includes a new GMP manufacturing suite, increasing the facility footprint by 20% and featuring an ISO-7 cleanroom for preparative HPLC chromatography and lyophilization. This development supports peptide projects from development to GMP manufacturing using solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), or hybrid approaches. The facility is designed with a three-step strategy for peptide drug candidate development, utilizing automated SPPS technology for proof-of-concept and LPPS synthesized technology to accelerate development and reduce manufacturing costs.
Why It's Important?
The expansion of Cambrex's peptide manufacturing capabilities is significant for the pharmaceutical industry, as it enhances the company's ability to produce peptide therapies efficiently and cost-effectively. By utilizing LPPS technology, Cambrex reduces solvent demand and the need for excess reagents compared to standard solid-state peptide synthesis processes. This innovation allows Cambrex to leverage its large manufacturing capacity to deliver peptide therapies to a broader patient population. The investment in R&D across complex synthetic modalities, including artificial intelligence for optimizing oligonucleotide processes, positions Cambrex as a leader in peptide manufacturing and innovation.
AI Generated Content
Do you find this article useful?
